Sana Biotechnology Appoints Brian Piper as CFO; Aptevo CEO Marvin White to Step Down in April; Violett Names Scott Kushino CEO
Brian Piper was appointed CFO and executive vice president at Sana Biotechnology, while Marvin White will step down as Aptevo CEO in April, succeeded by COO Jeff Lamothe. Additionally, Scott Kushino became CEO of Seattle startup Violett, and several other leadership changes occurred across Seattle and New York tech companies.
Sana Biotechnology Opens $80M Manufacturing Facility in Bothell to Scale Cancer and Gene Therapy Production
Sana Biotechnology inaugurated its new 80,000 square-foot manufacturing facility in Bothell, Washington, dedicated to producing its proprietary cancer drug program and future therapies. The company, known for its gene-editing technology and multiple drugs in human trials including for cancer, autoimmune diseases, and type 1 diabetes, sees this expansion as a key step in advancing scalable cell and gene therapies.
Sana Biotechnology Cuts 15% of Workforce and Shuts Heart Failure Program to Focus on Clinical Trials
Sana Biotechnology, a Seattle-based cell and gene therapy company, is cutting 15% of its workforce by the end of the year and shutting down a heart failure program as it shifts focus to clinical-stage development. Despite laying off 75 to 80 employees, Sana has sufficient cash runway to last into 2025 after raising $587 million in its 2021 IPO.
Organizations
-
Sana Biotechnology Co-founder and President and Chief Executive Officer · current
Questions about Steve Harr
Who is Steve Harr?
Steve Harr is Co-founder and President and Chief Executive Officer at Sana Biotechnology.
Which organizations is Steve Harr associated with?
On Seattle Flow, Steve Harr is listed with Sana Biotechnology.
Where is Steve Harr based?
Steve Harr is based in Seattle.